|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial显示文摘 | Martin Reck Rolf Kaiser Anders Mellemgaard Jean-Yves Douillard Sergey Orlov Maciej Krzakowski Joachim von Pawel Maya Gottfried Igor Bondarenko Meilin Liao Claudia-Nanette Gann José Barrueco Birgit Gaschler-Markefski Silvia Novello | 2014 | Lancet Oncology2014，，2： | 1 |
| 2 | Docetaxel plus nintedanib versus doeetaxel plus placebo in patientswith previously treated non-small-cell lung cancer ( LUME-Lung l ) : a phase 3, double-blind, randomised controlled trial 显示文摘 | Reek M Kaiser R Mellemgaard A | 2014 | Lancet Oncol2014，15，2： | 1 |
| 3 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non- small-cell lung cancer ( LUME-Lung 1 ) : a phase 3, double-blind, randomised controlled trial显示文摘 | Reck M Kaiser R Mellemgaard A | 2014 | Lancet Oncol2014，15，2： | 1 |
| 4 | Obesity and cancer risk: a Danish record-linkage study显示文摘 | Moller H Mellemgaard A Lindvig K | 1994 | Eur J Cancer1994，30，3： | 1 |
| 5 | Obesity and cancer risk: a Dan- ish record-linkage study 显示文摘 | Mgller H Mellemgaard A Lindvig K | 1994 | Eur J Can- cer1994，30，3： | 1 |
| 6 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non- small cell lung cancer ( LUNE-Lung 1 ) : a phase 3, double-blind, randomised controlled trial显示文摘 | Reck M Kaiser R Mellemgaard A | 2014 | Lancet Oncol2014，15，2： | 1 |
| 7 | Efficacy and safety of patupilone in non-sinai celung cancer (NSCLC): a phase l/III trial 显示文摘 | Sanchez JM Mellemgaard A Perry M | 2006 | J Clin Oncol2006，，： | 1 |
| 8 | Anti-angiogenic-speeific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel 显示文摘 | Reck M Mellemgaard A von Pawel J | 2015 | Lung Cancer2015，90，2： | 1 |
| 9 | Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine显示文摘 | Holm B Mellemgaard A Skov T | 2009 | J Clin Oncol2009，27，26： | 1 |
| 10 | Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis显示文摘 | Sanjay Popat Anders Mellemgaard Kyle Fahrbach Alison Martin Maria Rizzo Rolf Kaiser Ingolf Griebsch Martin Reck | 2015 | Future Oncol2015，，3： | 1 |
| 11 | Review of thyroid cancer eases among patients with previous benign thyroid disorders显示文摘 | From G Mellemgaard A Knudsen N | 2000 | Thyroid2000，10，： | 1 |
| 12 | Cancer incidence in men with Klinefelter syndrome显示文摘 | Hasle H Mellemgaard A Nielsen J | 1995 | Br J Cancer1995，71，： | 1 |
| 13 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non - small - cell lung cancer( LUME - Lung 1 ) :A phase 3 ,doub- le - blind, randomised controlled trial 显示文摘 | Reck M Kaiser R Mellemgaard A | 2014 | Lancet Oncol2014，15，2： | 1 |
| 14 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non - small - cell lung cancer ( LUME - Lung 1 ) : A phase 3, double - blind, randomised controlled trial 显示文摘 | Reck M Kaiser R Mellemgaard A | 2014 | Lancet Oncol2014，15，2： | 1 |
| 15 | Review of thyroid cancer cases among patients with previous benign thyroid disorders 显示文摘 | From G Mellemgaard A Knudsen N | 2000 | Thyroid2000，10，8： | 1 |
| 16 | Incidence of second primary cancer following testicular cancer显示文摘 | Moiler H Mellemgaard A Jacobsen GK | 1993 | Eur J Cancer1993，29，5： | 1 |
| 17 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1) : a phase 3, double-blind, randomised controlled trial 显示文摘 | Reck M Kaiser R Mellemgaard A | 2014 | Lancet Oncol2014，15，2： | 1 |
| 18 | Analysis of patient-repor- ted outcomes from the LUME Lung 1 trial: A randomised, double- blind, placebo controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer 显示文摘 | Novello S Kaiser R Mellemgaard A eta/ | 2015 | European Journal of Cancer2015，51，： | 1 |
| 19 | Dietary risk factors for renal cell carcinoma in Denmark显示文摘 | Mellemgaard A Mclaughlin JK Overvad K | 1996 | Eur J Cancer1996，32，4： | 1 |
| 20 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1 ) : a phase 3, double-blind, randomised controlled trial显示文摘 | Reck M Kaiser R Mellemgaard A | 2014 | Lancet Oncol2014，15，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员